ST. LOUIS, Oct. 22, 2012 (GLOBE NEWSWIRE) -- ISTO Technologies, Inc. announced today that it is initiating a Phase II trial to further evaluate the efficacy and safety of its NuQu® cell-based therapy for the treatment of pain and disability associated with degenerated spinal discs. The company expects to commence enrollment in the randomized, double-blinded, placebo-controlled trial in the fourth quarter of 2012. Interim results are expected by the end of 2013.
